Dr. William Prather, Senior VP of Corporate Development at Pluristem Therapeutics, a biotechnology company that is developing off-the-shelf cell therapies for a variety of human diseases joins eHealth Radio and the Health News Channel. Pluristem’s cell products are derived from human placentas, traditionally left to be medical waste following childbirth.
Dr. Prather will share how these cells work for a host of diseases and hopefully help save the lives of premature babies.
Listen to interview with host Eric Michaels & guest Dr. William Prather discuss the following:
- We have heard of all types of stem cells using embryonic eggs to bone marrow, can you explain the new advance using placental stem cells?
- What types of health conditions do the PLX cells address? How do the cells work to remedy the condition?
- How will these cells help with sports injuries?
- You recently announced that early studies showed the PLX cells reversed preeclampsia, a common condition among pregnant women, can you explain how?
- What is next for Pluristem?
William R. Prather RPh, MD, Senior VP Corporate Development, at Pluristem Therapeutics, is a Registered Pharmacist as well as a Board Certified Internist and Geriatrician. Dr. Prather received his BS in Pharmacy (1970) and medical degree (1973) from the University of Missouri. He practiced internal medicine in the Kansas City, MO and Vail, CO areas until leaving Internal Medicine in 1987 to pursue a Fellowship in Geriatric Medicine at Harvard University. He completed this Fellowship in 1989.
In 1992 Dr. Prather left the practice of medicine to pursue a career in the financial industry where he has held Senior Healthcare research positions for a variety of investment banks. Prior to joining Pluristem, Dr. Prather co-founded Panacos, Inc. (NASDAQ:PANC), a public pharmaceutical company. Additionally, he has been on the Boards of several public and private companies, including Boston Biomedica Inc. (a public medical diagnostics company), PriMed (a private medical device company), MdBio (a Maryland healthcare venture firm), and sat on the Advisory Board of MDS Capital Management, (a Canadian venture firm).